Skip to main content
Premium Trial:

Request an Annual Quote

News Scan: Feb 20, 2009

Premium

Millipore Licenses GeneGo Pathway Maps

GeneGo this week announced that it has licensed to Millipore 250 manually curated pathway maps for its new Interactive Biological Pathway tool, which has been launched on Millipore's website.

The new tool links Millipore's antibodies, proteins, assays, and relevant bioinformatics content related to biological pathways, said GeneGo. The maps are categorized by diseases and cellular processes to make it easier for researchers to find relevant information.

Terms of the license were not disclosed.


DiscoveryBioMed to Conduct Bioassay Testing for Lifeline

DiscoveryBioMed this week said that it has inked a service contract with Lifeline Cell Technology to conduct primary human cell bioassay testing for the subsidiary of International Stem Cell Corp.

The contract partners DBM's expertise in assay development with Lifeline's expertise in producing optimized human adult and stem cell products, said Lifeline CEO Jeffrey Janus.

Birmingham, Ala.-based DBM also said that the partners are developing a mutual Small Business Innovation Research grant proposal based on using multiple human cell cultures derived from different tissues as an in vitro platform for testing pollutants, candidate therapeutics, and existing drugs for toxicity against cells.

Financial and other terms of the contract were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more